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copy of the spectacle prescription be given 
to the patient. However, the law does not 
require the release of a contact lens pre-
scription; this is left to the discretion of the 
optometrist. You may want to inquire 
about your doctor's policy regarding the 
contact lens prescription prior to the ex-
amination." A majority of the Board be-
lieves that such a notice requirement is 
necessary to ensure that patients are aware 
of this loophole in the law, noting that its 
Sacramento office has received numerous 
complaints from individuals who were un-
able to obtain a copy of their contact lens 
prescription. Because consumers often as-
sume that they are entitled to receive their 
prescriptions, the Board believes that the 
proposed notice is necessary to inform 
consumers of the law in this area. At this 
writing, the Board has not yet published 
notice of its intent to adopt this regulation 
in the California Regulatory Notice Reg-
ister. 
UCLA Optometry Refresher Course 
Update. The first segment of an optome-
try refresher course primarily designed for 
foreign-trained individuals is now com-
pleted. Forty-one students participated in 
the first part of the course, designed by the 
Board and the University of California 
and offered through the UCLA Health Sci-
ences Extension Program. [ 12:4 CRLR 
114 J Twenty of the students recently com-
pleted the national written basic science 
test (a requirement for licensure); one 
passed and eight others achieved scores 
just below a passing grade. The clinical 
portion of the program began in Septem-
ber and will conclude in April. UCLA 
reported that students are very positive 
about the class, and that the University 
will evaluate the program upon its conclu-
sion. 
■ RECENT MEETINGS 
At its November 20 meeting, the Board 
elected its officers for 1993. Thomas 
Nagy, OD, will continue as president; Jo-
seph Dobbs, OD, will serve as vice-presi-
dent; and John R. Anthony, OD, will serve 
as secretary. 
Executive Officer Karen Ollinger re-
ported on the Board's enforcement statis-
tics for the period of January through June 
1992. During this six-month period, the 
Board received 191 complaints regarding 
optometrists; a total of 643 complaints 
were pending from all prior periods. The 
Board closed a total of 64 complaints; of 
those, 27 resulted in mediated settlements, 
nine were categorized as violations (the 
Board issued two citations with a fine and 
three warning notices), five were referred 
to the Attorney General or other appropri-
ate agency, and 23 were considered un-
actionable. During the six-month period, 
the Attorney General's Office filed three 
accusations against optometrists; all three 
cases resulted in stipulated judgments 
with the optometrist receiving suspension 
and probation. 
The Board also continued its discus-
sion of Business and Professions Code 
section 655, which prohibits landlord-ten-
ant relationships, or any other kind of 
profit-sharing arrangement, between op-
tometrists and opticians. Previously, the 
Board and the Medical Board of 
California's Division of Allied Health 
Professions had disagreed on the proper 
interpretation of section 655. [ 12:4 CRLR 
115 J However, no additional review is 
anticipated at this time, since the Board's 
position is consistent with Attorney 
General's Opinion No. 80-417 (March 4, 
1981 ), and since the Board may establish 
further guidelines for optometrists under 
its direction, if necessary. 
■ FUTURE MEETINGS 
May 20--21 in San Diego. 
BOARD OF PHARMACY 
Executive Officer: Patricia Harris 
(916) 445-5014 
Pursuant to Business and Professions Code section 4000 et seq., the Board 
of Pharmacy grants licenses and permits 
to pharmacists, pharmacies, drug manu-
facturers, wholesalers and sellers of hypo-
dermic needles. It regulates all sales of 
dangerous drugs, controlled substances 
and poisons. The Board is authorized to 
adopt regulations, which are codified in 
Division 17, Title 16 of the California 
Code of Regulations (CCR). To enforce its 
regulations, the Board employs full-time 
inspectors who investigate accusations 
and complaints received by the Board. 
Investigations may be conducted openly 
or covertly as the situation demands. 
The Board conducts fact-finding and 
disciplinary hearings and is authorized by 
law to suspend or revoke licenses or per-
mits for a variety of reasons, including 
professional misconduct and any acts sub-
stantially related to the practice of phar-
macy. 
The Board consists of ten members, 
three of whom are public. The remaining 
members are pharmacists, five of whom 
must be active practitioners. All are ap-
pointed for four-year terms. 
In late December, Governor Wilson 
appointed Darlene Fujimoto to the Board; 
Fujimoto is a senior pharmacist and geri-
atric specialist at the University of Califor-
nia at Irvine Medical Center and consul-
tant pharmacist for Clinical Care Pharma-
cies, Inc. Also in December, Wilson reap-
pointed Janeen McBride to the Board; 
McBride is the western region health care 
specialist for American Drug Stores, Sav-
On Drugs. 
■ MAJOR PROJECTS 
Board to Restructure Enforcement 
Unit. At its October 14-15 meeting, the 
Board discussed its plans to seek a budget 
change proposal (BCP) which would en-
able it to augment its enforcement pro-
gram, which has not been expanded in at 
least ten years. [ 12:4 CRLR 117-18] Ac-
cording to the Board, the expansion is 
necessitated by an increase in the number 
of pharmacies and pharmacists, the estab-
lishment of new registration programs 
such as medical device retailers and phar-
macy technicians, and changes in the law 
governing the practice of pharmacy; fur-
ther, the Board expects that the new man-
datory patient consultation regulations 
which became effective on November I 
will alter the delivery of pharmacy care in 
California, increasing the visibility of the 
profession and the Board's role in protect-
ing the public safety. The Board concedes 
that its failure to expand the enforcement 
program to meet the number of new pro-
grams and licensees has resulted in the 
following problems: 
-Complaints are open too long; conse-
quently, investigation reports are not filed 
in a timely manner, negatively affecting 
public safety. Certain complaints that war-
rant undercover investigation may fail to 
be substantiated simply because the in-
spector cannot devote sufficient time to 
perform a thorough investigation or audit 
due to oppressive workload demands. As 
a result, pharmacists may be cautioned 
with an admonition or scheduled for an 
appearance before one of the Board's In-
terim Disciplinary Committees rather than 
disciplined through the formal adjudica-
tory process. 
-Drug audits are performed only in 
cases where severe shortages are sus-
pected based on the Bureau of Narcotic 
Enforcement reports for Schedule II drugs 
or purchases of excessively large quanti-
ties of certain controlled substances listed 
on the Board's wholesaler distribution re-
port. According to the Board, drug audits 
of Schedule III and IV drugs are even 
more rare, encouraging drug diversion. 
For example, the Board suspects that ste-
roids (Schedule III drugs) are being di-
verted from pharmacies in California for 
illegal sale; because the Board is no longer 
routinely auditing pharmacies' drug in-
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ventories, it is unable to take proactive 
strides to curtail this activity unless inves-
tigating a complaint. 
-Innovative enforcement issues are 
not being expeditiously addressed. For ex-
ample, in July 199 I, the Board issued a 
report on what seemed to be a widespread 
pattern of illegal kickbacks between phy-
sicians and home health care agencies for 
the referral of patients {11:4 CRLR 104; 
10:4 CRLR 98]; however, the Board's 
heavy workload precluded it from doing 
anything but investigate only the most 
pressing cases. Also, due to the delay in 
availability of Board staff, the FBl's "Op-
eration Goldpill" arrests were delayed at 
least 75 days past the nationwide press 
conference announcing the undercover in-
vestigation involving false Medicare bill-
ings and illegal sales of drugs. { 12:4 
CRLR 115] 
-The Board has not inspected all phar-
macies every three years, as is required by 
its policy. According to the Board, routine 
inspections have been eliminated entirely; 
inspections are conducted only when 
needed (to issue a new permit, in conjunc-
tion with an investigation, or as part of the 
terms of a licensee's probation). 
-Unless the complainant contacts the 
Board, the Board is not able to routinely 
provide feedback to those who initiate en-
forcement cases involving patient injury 
during the two and one-half years while 
cases are pending in the administrative 
disciplinary process; as a result, the Board 
appears nonresponsive to consumers 
about the more serious complaints in 
which accusations are filed. 
-Board staff members are required to 
spend inordinate amounts of time travel-
ing in order to cover huge territories; for 
example, one inspector covers the entire 
territory from Orange County south to the 
Mexican border and east to Arizona. 
-Unlicensed activity by medical de-
vice retailers (MDRs) is going unen-
forced. Despite the program's im-
plementation in July 1991, the Board esti-
mates that a minimum of 200 firms are 
working unlicensed as MDRs. 
The Board noted that it has no special-
ized complaint intake staff to receive, 
refer, or resolve complaints and inquiries. 
Instead, its inspectors handle nearly all 
calls and written inquiries regarding en-
forcement and pharmacy law interpreta-
tion, as well as those from consumers with 
inquiries or problems with pharmacists, 
pharmacies, and pharmaceutical products. 
Currently, incoming calls are routed to an 
inspector in either the Board's Sacramento 
or Los Angeles office. Calls average seven 
per workday to each of the Board's thir-
teen inspectors, and approximately fifteen 
per day to each of the two supervising 
inspectors who are generally office-
bound. The Board notes that these are new 
inquiries, not follow-up responses regard-
ing investigations and inspections already 
in progress with the inspectors. 
As a result, the Board is planning to 
restructure its enforcement unit by estab-
lishing a public inquiry component and 
increasing its inspector staff. The Board 
plans to redirect the initial intake of tele-
phone and written complaints from the 
pharmacy inspectors and instead hire a 
consumer service representative and of-
fice technician to respond to such inquir-
ies, track complaints and cases, and pre-
pare periodic correspondence to update 
those who have contacted the Board. Also, 
the Board notes that its inspection staff 
must be increased to enable it to investi-
gate complaints expeditiously, conduct 
random and periodic inspections of phar-
macies, and perform drug audits. 
At its October meeting, the Board 
agreed to pursue the BCP and to institute 
the rulemaking process to increase licens-
ing fees in order to generate funding for 
the additional staff; at this writing, notice 
of the proposed fee increase has not been 
published in the California Regulatory 
Notice Register. 
Rapid Rise in Drug Prices May Prod 
Legislation. Over the past nine years, 
prices of prescription drugs have risen at 
nearly three times the consumer price 
index (CPI). Although they account for 
only approximately 5% of total health care 
costs, prescription drugs have attracted 
consumer attention because insurance 
typically does not cover their cost. Con-
gress has mandated that drug manufactur-
ers extend to Medicaid the same discounts 
offered to volume buyers such as health 
maintenance organizations and hospitals. 
U.S. Senator David Pryor (D-Arkansas) 
may reintroduce legislation from last ses-
sion that could deny billions of dollars in 
tax credits to those companies whose drug 
prices increase at a faster rate than the CPI. 
In anticipation of such legislation, some 
drug companies have promised to keep 
their price increases in line with the CPI. 
Patient Consultation Regulations. 
On October 14, the Board held a public 
hearing on its proposed amendments to 
sections 1707. I and 1707 .2, and its pro-
posed adoption of section 1707 .3, Title 16 
of the CCR, regarding its patient consul-
tation requirements. According to the 
Board, the proposed changes would align 
existing California pharmacy regulations 
with provisions of the federal Omnibus 
Budget Reconciliation Act of 1990 
(OBRA 90) which establish patient con-
sultation by pharmacies as a requirement 
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for Medicaid-covered patients and specify 
required and permissive duties for phar-
macists in this regard. {12:4 CRLR 115-
16} At the hearing, the Board received 
extensive testimony on the proposals from 
representatives of the County of Orange 
Health Care Agency, the California Retail-
ers Association, Kaiser Permanente Med-
ical Care Program, the California Pharma-
cists Association, and the California Asso-
ciation of Public Hospitals. Following 
consideration of the comments received, 
the Board adopted the proposed regula-
tory changes subject to minor modifica-
tions. The Board released the revised text 
for an additional fifteen-day public com-
ment period; the revisions await review 
and approval by the Office of Administra-
tive Law (OAL). 
Compounding for Office Use Regu-
lations. On June 22, OALdisapproved the 
Board's proposal to adopt new sections 
1716.1 and 1716.2, Title 16 of the CCR. 
Section 1716.1 would define the quantity 
of compounded medication which a phar-
macist may furnish to a prescriber for of-
fice use under Business and Professions 
Code section 4046( c )(I), and section 
1716.2 would specify the minimum types 
of records that pharmacies must keep 
when they furnish compounded medica-
tion to prescribers in quantities larger than 
required for the prescriber's immediate 
office use or when a pharmacy compounds 
medication for future furnishing. Among 
other things, OAL rejected the sections on 
the basis that they failed to meet the clarity 
and necessity standards of the Administra-
tive Procedure Act. {12:4 CRLR 116] 
At its October meeting, the Board dis-
cussed the issues raised by OAL. Execu-
tive Officer Patricia Harris explained that 
in order to resolve OAL's concerns, staff 
made various revisions that needed Board 
approval. The two major changes (I) add 
language specifying that the term "com-
pounding for prescriber officer use" per-
tains only to unapproved drugs, and (2) 
delete language providing that the term 
"compounded medication" also means 
repackaging for administration or applica-
tion to a patient in the prescriber's office 
or for dispensing not more than a 72-hour 
supply to the prescriber's patient. The 
Board approved the amended language; at 
this writing, the sections await resubmis-
sion to OAL. 
Pharmacist-in-Charge Regulations. 
The Board's amendment to section 
1709.1, Title 16 of the CCR, to allow a 
pharmacist to be the pharmacist-in-charge 
at two pharmacies if only one of these 
pharmacies is open at any given time and 
if the pharmacist is the only pharmacist at 
each pharmacy, was approved by OAL on 
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December 11. [12:4 CRLR 116] 
Medical Device Retailers' Locked 
Storage Regulations. The Board's 
rulemaking file regarding its proposed 
adoption of new sections 1748.1 and 
1748.2, Title 16 of the CCR, regarding the 
proper storage of dangerous devices at 
medical device retailer (MDR) retail sites 
and the delivery of devices by MDRs to 
patients after hours or in emergency situ-
ations, was submitted to OAL in mid-De-
cember. [12:4 CRLR 117] 
FDA Responds to Concerns About 
Wholesaler Licenses. In June 1992, OAL 
approved the Board's regulatory amend-
ments to section 1780, Title 16 of the 
CCR, which change California's require-
ments for drug wholesalers so that they 
meet or exceed the standards of the federal 
government under the Prescription Drug 
Marketing Act of 1987. [ 12:4 CRLR 116] 
Also to comply with federal requirements, 
the Board obtained statutory changes to 
Business and Professions Code section 
4038 to delete the exemption of pharma-
cies and licensed manufacturers from the 
definition of the term "wholesaler," 
through the passage of AB 2743 (Frazee) 
(Chapter 1289, Statutes of 1992). [ 12:4 
CRLR 117] As a result, pharmacies which 
engage in specified activities are subject 
to Business and Professions Code section 
4084, which provides that no person shall 
act as a drug wholesaler unless he/she has 
obtained a certificate, license, permit, reg-
istration, or exemption from the Board. 
In response to its actions, the Board 
received inquiries from small indepen-
dently-owned pharmacies regarding how 
the Board will detennine that a phannacy 
should be licensed as a wholesaler if that 
phannacy engages in the following com-
mon practices: (I) sells legend drugs at 
wholesale prices to another phannacy to 
cover an out-of-stock situation of the buy-
ing pharmacy; (2) purchases a volume 
deal at a very good price from the manu-
facturer but cannot use the entire amount 
purchased and therefore sells the surplus 
to one or more other phannacies at the 
"deal" price; and (3) sells vaccines, che-
motherapeutic agents, or compounded or 
repackaged legend drugs to a prescriber 
for office use and/or dispensing to the 
ultimate consumer. 
In response to these inquiries, Board 
Executive Officer Patricia Harris asked 
the Food and Drug Administration (FDA) 
for clarification as to how the Board 
should detennine that a phannacy is en-
gaged in "wholesale" operation and is thus 
required to be licensed as a wholesaler. At 
its October meeting, the Board reviewed 
the FDA's response, which answered each 
question as follows: 
(I) Section 205.3(f)(5) of the federal 
"Guidelines for State Licensing of Whole-
sale Prescription Drug Distributors" (Li-
censing Guidelines) states that wholesale 
distribution does not include the sale, pur-
chase, or trade of a drug or an offer to sell, 
purchase, or trade a drug for emergency 
medical reasons; the term "emergency 
medical reasons" includes transfers of pre-
scription drugs by a retail phannacy to 
another retail phannacy to alleviate a tem-
porary shortage. Therefore, sales from one 
retail pharmacy to another to alleviate a 
temporary out-of-stock situation meets 
the "emergency medical reasons" crite-
rion of the Licensing Guidelines and does 
not require the selling retail pharmacy to 
be licensed as a wholesale distributor. 
(2) Section 205.3(f) of the Licensing 
Guidelines defines "wholesale distribu-
tion" as the distribution of prescription 
drugs to persons other than a consumer or 
patient. The FDA noted that this section 
contains eight exceptions, and unless one 
of these exceptions is met by the selling 
retail pharmacy, the sales are considered 
wholesale distribution and the retail phar-
macy must be licensed accordingly. 
(3) Neither the federal Food, Drug, and 
Cosmetic Act nor the federal Licensing 
Guidelines address the sale of prescription 
drugs by retail pharmacies to licensed 
practitioners for office use. According to 
the FDA, "[i]n the interests of avoiding 
undue interference with nonnal business 
practices in the health care field, ... the sale 
of minimal quantities of prescription 
drugs by a retail pharmacy to licensed 
practitioners for office use is not whole-
sale distribution as contemplated by the 
[Prescription Drug Marketing Act]." The 
FDA stated its "present position that sales 
by a retail phannacy to licensed practition-
ers of prescription drugs for office use will 
not be considered wholesale distribution 
requiring state licensing if the total annual 
dollar volume of prescription drugs sold 
to licensed practitioners does not exceed 
five percent of that retail pharmacy's total 
annual prescription drug sales." 
At the meeting, California Pharmacist 
Association (CPhA) representative David 
Keast commented that the FD A's response 
did not provide any regulatory citation 
which provides a basis for the 5% annual 
dollar volume; Keast noted that CPhA 
would like to work with the Board and 
national organizations to persuade the 
FDA to take an alternative approach to the 
5% annual dollar volume and how it is 
measured in order to allow small pharma-
cies to continue in the way that they prac-
tice phannacy. 
The Board also discussed that under 
the FDA's position, a pharmacy could no 
longer purchase volume deals to split be-
tween other phannacies, unless the phar-
macy has a wholesale license. Board 
members noted that small phannacies un-
able to buy products in large volume will 
be adversely affected by the wholesale 
licensure requirement. Following discus-
sion, the Board directed staff to inform the 
FDA of its concerns regarding the im-
plications of the requirements. 
■ LEGISLATION 
Future Legislation. The Department 
of Consumer Affairs (DCA) has agreed to 
carry amendments in its 1993 omnibus bill 
regarding the provision of oral consulta-
tion to patients by a pharmacist when med-
ications are delivered by mail. [ 12:4 
CRLR I 16] The language would state that 
any phannacy which ships or mails pre-
scriptions to a resident of California shall 
provide telephone service, including a 
toll-free number for any long distance 
telephone calls, at least six days per week 
between the hours of 9:00 a.m. and 6:00 
p.m. for patients to consult a pharmacist 
who has access to the patient's records. 
Written notice of the right to consultation 
and the toll-free number for long distance 
calls shall be included with or affixed to 
each container of drugs dispensed by mail. 
Also as part of its omnibus bill, DCA 
plans to sponsor legislation that would 
give the Board authority to issue interim 
orders of license suspension. Although the 
Medical Board of California has such au-
thority, the only option presently available 
to the Board of Phannacy when a licensee 
poses a serious threat to the public safety 
is to obtain a temporary restraining order 
through the superior court. Proposed sec-
tion 494 of the Business and Professions 
Code would permit the Board to issue an 
interim order suspending a license if affi-
davits in support of the petition show that 
the licensee has engaged in, or is about to 
engage in, acts or omissions constituting 
a violation of a provision of the Business 
and Professions Code or has been con-
victed of a crime substantially related to 
the practice of the I icensee' s profession or 
occupation, and that permitting the licen-
see to continue to engage in practice 
would endanger the public health, safety, 
or welfare. 
■ LITIGATION 
At its October 15 meeting, the Board 
went into closed session to consult with its 
legal counsel regarding Californians for 
Sa/ e Prescriptions v. California State 
Board of Pharmacy, No. BS0l9433, filed 
in Los Angeles County Superior Court in 
September. The petitioner, a nonprofit or-
ganization consisting of approximately 
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5,000 California-licensed pharmacists, 
sought a writ of mandamus and declara-
tory and injunctive relief in relation to the 
Board's alleged failure to comply with the 
Administrative Procedure Act (APA) in 
promulgating its pharmacy technician 
regulations. 
Pursuant to its authority in Business 
and Professions Code sections 4008 and 
4008.2, the Board attempted in 1989 to 
promulgate regulations denominated sec-
tions 1717 and 1793-1793.7, Title 16 of 
the CCR, which would establish a new 
licensing category of individuals who 
could perform dispensing-related tasks in 
pharmacies under the supervision of li-
censed pharmacists. [9:4 CRLR 75 J How-
ever, over the next two years, OAL disap-
proved the proposed rules on three occa-
sions, finding that they conflicted with 
statutes providing that only licensed phar-
macists may compound and dispense 
medications. [II: 2 CRLR 97-98; 11: 1 
CRLR 83 J The Board then sponsored leg-
islation authorizing it to promulgate the 
pharmacy technician regulations. Subse-
quently, AB 1244 (Polanco) (Chapter 841, 
Statutes of 1991) was enacted, authorizing 
pharmacy technicians to perform speci-
fied tasks. [ 11 :4 CRLR 105-06] The 
Board re-proposed its pharmacy techni-
cian regulations in December 1991, held 
a public hearing on them in January 1992, 
adopted them subject to an additional 15-
day public comment period, and resubmit-
ted its proposed regulations to OAL in 
April 1992. OAL again rejected the regu-
lations in June. Shortly after OAL's June 
disapproval, petitioner requested that an-
other public hearing be held-pursuant to 
Government Code section 11349.4-
prior to the Board's revision of the regula-
tions and resubmission to OAL. Petitioner 
contended that the revisions would have 
to be significant to remedy OAL's objec-
tions, and that public discussion was 
therefore necessary. 
On June 17, the Board modified its 
regulations and released the modified text 
for a 15-day comment period; it did not 
schedule another public hearing. Peti-
tioner again requested a public hearing, 
this time pursuant to Government Code 
section 11346.8(a), and identified several 
provisions of the proposed regulations 
which were allegedly in conflict with the 
Board's enabling statute or were vague 
and ambiguous and needed clarification. 
The Board resubmitted the regulations to 
OAL without conducting an additional 
public hearing. On August 12, OAL ap-
proved the regulations as amended. Peti-
tioner contended that, because a timely 
request was made pursuant to Govern-
ment Code sections 1 I 346.8(a) and 
11349.4, a writ of mandamus is warranted 
ordering the Board to hold public hearings 
before implementing the regulations. 
Petitioner also contended that the reg-
ulations must be declared invalid under 
Government Code section 11350 on the 
basis that they do not comply with the 
standards of consistency and clarity re-
quired of all regulations by the APA. Spe-
cifically, Petitioner contended that: 
-Section 1793.2 of the regulations per-
mits pharmacy technicians to perform vir-
tually all the functions of a registered 
pharmacist; such a regulation is inconsis-
tent with the legislative intent of Business 
and Professions Code section 4008.5. 
-Allowing pharmacy technician appli-
cants to qualify for registration based 
upon previous experience as a clerk-typist 
in a pharmacy is inconsistent with the 
legislative intent of Business and Profes-
sions Code section 4008.5([), which re-
quires applicants to have experience 
equivalent to employment as a pharmacy 
technician in assisting in the filling of 
prescriptions for an inpatient of a hospital 
or for an inpatient of a correctional facil-
ity. 
-The regulations are inconsistent with 
legislative intent in that they permit the 
registration of a technician who has not 
obtained an associate of arts degree in a 
field of study directly related to the duties 
performed by a pharmacy technician. 
-The regulations are inconsistent with 
legislative intent in that they permit regis-
tration of a technician who has had less 
than the one year of experience required 
by Business and Professions Code section 
4008.S(f)( l)(D). 
-The legislative requirement that a 
pharmacy technician be within the phar-
macist's view at all times is not clearly or 
consistently implemented by the Board's 
proposed regulation requiring pharma-
cists to be fully aware of all activities 
involved in the preparation and dispensing 
of medications, including the mainte-
nance of appropriate records. 
-Language in the regulations requiring 
that only a registered pharmacist may 
identify, evaluate, and interpret a prescrip-
tion lacks sufficient clarity to satisfy Gov-
ernment Code section 11349(c). 
Finally, Petitioners requested that the 
court issue a preliminary injunction en-
joining the Board from implementing the 
regulations until further order of the court. 
On November 2, the matter was heard 
by the Los Angeles County Superior 
Court; on December 15, the court entered 
judgment in the Board's favor. Among 
other things, the court held that the Board 
followed and complied with the APA in 
promulgating and adopting the pharmacy 
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technician regulations; the Board was not 
legally compelled to hold a second hear-
ing after the rejection of the regulations by 
OAL and their revision by the Board, as 
each change to the proposed regulations 
made by the Board was sufficiently related 
to the original text of the regulation that 
the public was adequately placed on no-
tice the change could result from the orig-
inally proposed regulatory action; nothing 
in the regulations is inconsistent with the 
language or intent of Business and Profes-
sions Code section 4008.5; and the regu-
lations do not lack clarity. 
In Huggins v. Longs Drug Stores Cal-
ifornia, Inc., No. F016033 (Dec. 4, 1992), 
the Fifth District Court of Appeal held that 
a pharmacist's provision of incorrect dos-
age amounts for a prescription which the 
pharmacist knows or should know will be 
administered to an infant by the infant's 
parents constitutes negligent action di-
rected at the parent caregivers, which may 
allow the caregivers to recover damages 
for negligent infliction of emotional dis-
tress. 
Barbie and Robert Huggins' two-
month-old son Kodee received an over-
dose of an antibiotic as a result of the 
pharmacy's negligence in providing in-
structions for medication dosage. The par-
ents sued the pharmacy for damages for 
negligent infliction of emotional distress; 
in the complaint, the parents alleged that 
the pharmacy owed them a duty due to 
their relationship with the pharmacy. 
However, the trial court granted the 
pharmacy's motion for summary judg-
ment, concluding that the parents failed to 
establish the elements necessary to sup-
port a cause of action for negligent inflic-
tion of emotional distress; the court held 
that the parents could not recover under 
the "bystander theory" because there was 
"no contemporaneous connection be-
tween the negligent act and the injury," 
and "[p]laintiffs cannot recover under a 
'direct victim' theory as the duty not to be 
negligent is owed to their child." 
On appeal, the Fifth District agreed 
that the parents may not recover under the 
bystander theory, under which the plain-
tiff's emotional distress results from a di-
rect emotional impact from the sensory 
and contemporaneous observance of an 
accident, as contrasted with learning of the 
accident from others after its occurrence. 
The court noted that "the parents did not 
suffer emotional distress because of the 
overdose until they learned of the over-
dose from third parties." 
However, the court noted that a much 
closer question is presented by the parents' 
alternative theory-that recovery is per-
missible under the "direct victim" theory; 
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the parents contended that the pharmacist, 
by providing the dosage amounts, as-
sumed a duty to them because he knew or 
should have known they would have to 
administer the prescription to their infant 
son and would do so in accordance with 
his direction. The court agreed with this 
argument, finding that "the action of a 
pharmacist, in providing incorrect dosage 
under circumstances making it necessary 
for a caregiver to administer the medica-
tion, would constitute negligence directed 
at the caregiver who did so administer." 
The court found that "[i]t would be ludi-
crous to argue that an infant of two months 
could either take the medication without 
help or could comprehend the misdirec-
tion of the dosage. Therefore, under those 
circumstances, the negligent giving of in-
structions to the Huggins is, by its very 
nature, directed at the parents, rather than 
solely at the infant." 
In reviewing the public policy im-
plications of its holding, the court noted 
that it discerned "no public policy war-
ranting insulation from liability of a phar-
macist who provides instructions for a pre-
scription intended for an infant and who 
negligently misstates the dosage, setting 
in motion a process which results in death 
or serious injury to the child. Rather, we 
hold that a parent or close relative who, as 
a caregiver, relies upon the directions and 
administers the prescription should be al-
lowed recovery under such circum-
stances." 
■ RECENT MEETINGS 
At the Board's October 14 meeting, 
representatives of Hoag Memorial Hospi-
tal requested that the Board issue a hospi-
tal pharmacy permit to Hoag's Cancer 
Center, which provides outpatient ser-
vices on its hospital license. In February 
1992, Hoag's first such request was de-
nied. Since the Center is not physically 
part of the hospital, the Board found that 
the drug distribution procedures were not 
acceptable insofar as patients at the Center 
are considered outpatients and the phar-
macy must dispense drugs via a prescrip-
tion instead of a chart order. At the Octo-
ber meeting, the Board again rejected 
Hoag's request, stating that current law 
does not authorize the Board to issue a 
hospital pharmacy permit unless the phar-
macy is physically located in the hospital. 
Deputy Attorney General William Marcus 
added that unless a statutory change is 
made, the Board lacks authority to issue a 
pharmacy permit for Hoag's proposed dis-
tribution system; Marcus recommended 
that Hoag work with other interested par-
ties to pursue such a change. 
■ FUTURE MEETINGS 
July 28-29 in Sacramento. 
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The Board of Registration for Profes-sional Engineers and Land Surveyors 
(PELS) regulates the practice of engineer-
ing and land surveying through its admin-
istration of the Professional Engineers Act, 
sections 6700 through 6799 of the Busi-
ness and Professions Code, and the Pro-
fessional Land Surveyors' Act, sections 
8700 through 8805 of the Business and 
Professions Code. The Board's regulations 
are found in Division 5, Title 16 of the 
California Code of Regulations (CCR). 
The basic functions of the Board are to 
conduct examinations, issue certificates, 
registrations, and/or licenses, and appro-
priately channel complaints against regis-
trants/licensees. The Board is additionally 
empowered to suspend or revoke registra-
tions/licenses. The Board considers the 
proposed decisions of administrative Jaw 
judges who hear appeals of applicants who 
are denied a registration/license, and those 
who have had their registration/license 
suspended or revoked for violations. 
The Board consists of thirteen mem-
bers: seven public members, one licensed 
land surveyor, four registered Practice Act 
engineers and one Title Act engineer. 
Eleven of the members are appointed by 
the Governor for four-year terms which 
expire on a staggered basis. One public 
member is appointed by the Speaker of the 
Assembly and one by the Senate Rules 
Committee. 
The Board has established four stand-
ing committees and appoints other special 
committees as needed. The four standing 
committees are Administration, Enforce-
ment, Examination/Qualifications, and 
Legislation. The committees function in 
an advisory capacity unless specifically 
authorized to make binding decisions by 
the Board. 
Professional engineers are registered 
through the three Practice Act categories 
of civil, electrical, and mechanical engi-
neering under section 6730 of the Busi-
ness and Professions Code. The Title Act 
categories of agricultural, chemical, con-
trol system, corrosion, fire protection, in-
dustrial, manufacturing, metallurgical, 
nuclear, petroleum, quality, safety, and 
traffic engineering are registered under 
section 6732 of the Business and Profes-
sions Code. 
Structural engineering and geotechni-
cal engineering are authorities linked to 
the civil Practice Act and require an addi-
tional examination after qualification as a 
civil engineer. 
■ MAJOR PROJECTS 
PELS to Interview Prospective Ex-
ecutive Officers. PELS is continuing its 
efforts to fill the Executive Officer (EO) 
position vacated by Darlene Stroup in Au-
gust 1992. [12:4 CRLR 118] At PELS' 
November 20 meeting, Interim EO Curt 
Augustine reported that the Board had re-
ceived 178 applications for the position. 
At this writing, the semifinal round of 
interviews for the position is scheduled to 
be held in Sacramento on January 14-15, 
with final interviews taking place in Los 
Angeles on January 28. 
PELS Adopts Policy Regarding Dis-
advantaged Business Enterprises. At its 
November 20 meeting, the Board re-
viewed an opinion of the Department of 
Consumer Affairs' (DCA) Legal Office 
regarding whether the Professional Engi-
neers Act or Professional Land Surveyors' 
Act permits an unregistered person who is 
a part owner of a professional engineering 
or land surveying business to qualify the 
business as a minority-owned, women-
owned, or disadvantaged business enter-
prise (DBE) in order to obtain state con-
tracts. DCA previously concluded that an 
unregistered person may be a part owner 
or manager of a professional business, 
provided (1) there is a professional engi-
neer as an owner, part owner, or officer in 
charge of the engineering practice of the 
business; (2) all engineering work is pre-
pared under the responsible charge of a 
professional engineer in the appropriate 
branch of professional engineering; and 
(3) the unregistered person limits his/her 
managerial role to aspects of the business 
which do not involve the practice of pro-
fessional engineering. 
However, recently-enacted AB 486 
(Polanco) (Chapter 1329, Statutes of 
1992) creates uniform certification cri-
teria for DBE firms hired by state agencies 
and defines the requisite control which 
must be exercised by a disadvantaged 
owner to qualify the firm as a DBE; the 
new Jaw cites Part 23, Title 49 of the Code 
of Federal Regulations as the source of the 
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